Abstract:The classes of neuropharmaceuticals known as proteins and peptides serve as diagnostic tools and are involved in specific communication in the peripheral and central nervous systems. However, due to tight junctions resembling epithelial cells found in the blood-brain barrier (BBB) in vivo, they are typically excluded from transport from the blood to the brain. The drugs having molecular weight of less than 400 Dalton are able to cross the BBB via lipid-mediated free diffusion. However, large molecule therapeutics are devoid of these characteristics. As an alternative, these substances may be carried via chimeric peptide drug delivery systems, and assist in transcytosis through BBB with the aid of linker strategies. With their recent developments, several forms of nanoparticles, including poly (ethylene glycol)-poly(<i>ε</i>-caprolactone) copolymers, nanogels, liposomes, nanostructured lipid carriers, poly (D, L-lactide-co-glycolide) nanoparticles, chitosan, and solid lipid nanoparticles, have also been considered for their therapeutic applications. Moreover, the necessity for physiologic optimization of current drug delivery methods and their carriers to deliver therapeutic doses of medication into the brain for the treatment of various neurologic illnesses has also been emphasized. Therapeutic use of proteins and peptides has no neuroprotective impact in the absence of all these methods. Each tactic, however, has unique drawbacks and considerations. In this review, we discuss different drug delivery methods for therapeutic distribution of pharmaceuticals, primarily neuroproteins and neuropeptides, through endothelial capillaries via blood-brain barrier. Finally, we have also discussed the challenges and future perspective of protein and peptide therapeutics delivery to the brain. SIGNIFICANCE STATEMENT: Very few reports on the delivery of therapeutic protein and peptide nanoformulations are available in the literature. Herein, we attempted to discuss these nanoformulations of protein and peptide therapeutics used to treat brain diseases.

Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges

Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides

Local Delivery Strategies for Peptides and Proteins into the CNS: Status Quo, Challenges, and Future Perspectives

Recent developments in peptide drug delivery to the brain

Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

Harnessing the capacity of cell-penetrating peptides for drug delivery to the central nervous system.

Recent advances in delivery of peptide and protein therapeutics to the brain

Peptide-decorated Nanocarriers Penetrating the Blood-Brain Barrier for Imaging and Therapy of Brain Diseases.

Targeting Cerebral Diseases with Enhanced Delivery of Therapeutic Proteins Across the Blood-Brain Barrier

Advancements in drug delivery methods for the treatment of brain disease

Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies

Advances in Brain Delivery Systems Based on Biomimetic Nanoparticles

Nose-to-brain peptide delivery - The potential of nanotechnology

Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis

Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke

An Overview on the Physiopathology of the Blood–Brain Barrier and the Lipid-Based Nanocarriers for Central Nervous System Delivery

Blood–Brain Barrier-Targeting Nanoparticles: Biomaterial Properties and Biomedical Applications in Translational Neuroscience

Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: Insights and challenges

Biomaterials for Drugs Nose-Brain Transport: A New Therapeutic Approach for Neurological Diseases

Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation

Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands